Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.7K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.7K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

93
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
93
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

733
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
733

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma.

The New England journal of medicine·2026
Same author

CD8<sup>+</sup>CD38<sup>+</sup> T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates.

Blood neoplasia·2026
Same author

Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma.

Cancer·2026
Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same author

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

JAMA oncology·2026
Same author

Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?

Lancet (London, England)·2026

Related Experiment Video

Updated: Nov 27, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.3K

Defining and Managing High-Risk Multiple Myeloma: Current Concepts.

Luciano J Costa1, Saad Z Usmani2

  • 11Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama; and.

Journal of the National Comprehensive Cancer Network : JNCCN
|December 7, 2020
PubMed
Summary

High-risk multiple myeloma (HRMM) patients face poor outcomes. Current therapies include triplet regimens and stem cell transplant, with immunotherapy showing promise for better HRMM treatment strategies.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.1K

Related Experiment Videos

Last Updated: Nov 27, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.1K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Multiple myeloma is a heterogeneous plasma cell neoplasm.
  • A subset of patients, defined as high-risk multiple myeloma (HRMM), experiences poor therapeutic responses, frequent relapses, and reduced survival.
  • Indicators of HRMM include advanced International Staging System stage, specific chromosomal abnormalities (del(17p), t(4;14), t(14;16)), gene expression profiles, elevated lactate dehydrogenase, and extramedullary disease.

Purpose of the Study:

  • To review the current understanding and management of high-risk multiple myeloma (HRMM).
  • To highlight evolving risk stratification methods, including dynamic assessment based on measurable residual disease and PET/CT imaging.
  • To discuss established and emerging therapeutic strategies for HRMM.

Main Methods:

  • Review of current literature on multiple myeloma diagnostics, prognostics, and therapeutics.
  • Analysis of established indicators for high-risk disease.
  • Evaluation of recent advancements in risk assessment and treatment modalities.

Main Results:

  • High-risk multiple myeloma (HRMM) is characterized by specific genetic markers and clinical features.
  • Dynamic risk assessment, incorporating response to therapy and measurable residual disease, refines outcome prediction.
  • Current therapeutic pillars for HRMM include triplet therapies and autologous hematopoietic cell transplantation.
  • Anti-CD38 monoclonal antibodies demonstrate efficacy in HRMM.

Conclusions:

  • Effective management of HRMM requires a multi-faceted approach incorporating risk stratification and tailored therapies.
  • Immunotherapy, including anti-CD38 agents, offers a significant benefit in HRMM.
  • Future research directions focus on novel immunotherapeutic and non-immunotherapeutic agents, potentially integrated early in treatment paradigms for risk- and response-adapted HRMM management.